Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Noex vs Budecort Aqua in Allergic Rhinitis
NCT01022047Phase 3Completed
- Sponsor
- Eurofarma
- Start
- Feb 2010
- Primary completion
- Feb 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide in allergic rhinitis (AR) (2 arms), sponsored by Eurofarma. Primary endpoint: Nasal Index Score at 4 weeks. Started Feb 2010; status: completed.
02
Drugs
budesonide
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT01022047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01022047.